Medicine and Dentistry
Patient
100%
Myelodysplastic Syndrome
33%
Chronic Myelogenous Leukemia
33%
Topotecan
33%
Stomatitis
33%
Exatecan
33%
Cell Line
33%
Toxicity
16%
Tumor Progression
16%
Acute Myeloid Leukemia
16%
In Vitro
16%
Intravenous Drug Administration
16%
Hematologic Malignancy
16%
Diarrhea
16%
Growth Inhibition
16%
Acute Lymphoblastic Leukemia
16%
Hypoplasia
16%
Topoisomerase
16%
Camptothecin
16%
Cytarabine
16%
Antileukemic Agent
16%
Salicylate Sodium
16%
Age
16%
Recommended Drug Dose
16%
DNA Fragmentation
16%
SCID Mouse
16%
Agent Study
16%
Central Nervous System Leukemia
16%
Adult
16%
Acute Myelogenous Leukemia
16%
Water
16%
INIS
patients
100%
leukemia
66%
doses
66%
trioctylphosphine oxide
66%
humans
33%
mice
16%
in vitro
16%
tumor cells
16%
adults
16%
sensitivity
16%
dna
16%
water
16%
inhibition
16%
toxicity
16%
refractories
16%
infusion
16%
malignancies
16%
spectra
16%
growth inhibition
16%
blasts
16%
schedules
16%
diarrhea
16%
fragmentation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Myelodysplastic Syndrome
33%
Chronic Myeloid Leukemia
33%
Topotecan
33%
Stomatitis
33%
Exatecan
33%
Toxicity
16%
Acute Myeloid Leukemia
16%
Tumor Growth
16%
Prognosis
16%
Diarrhea
16%
Hematologic Malignancy
16%
SCID Mouse
16%
DNA Topoisomerase
16%
Camptothecin
16%
Mouse Model
16%
Cytarabine
16%
Acute Lymphoblastic Leukemia
16%
Central Nervous System Leukemia
16%
Salicylate Sodium
16%
Hypoplasia
16%
Water
16%